Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 29432.99 
• Atom Count: 2056 
• Residue Count: 249 
• Unique protein chains: 1

2OZ7

Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate

• DOI: 10.2210/pdb2OZ7/pdb

• Classification: HORMONE RECEPTOR
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): 1 


• Deposited: 2007-02-25 Released: 2007-03-27 
• Deposition Author(s): Bohl, C.E., Wu, Z., Miller, D.D., Bell, C.E., Dalton, J.T.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.8 Å
• R-Value Free: 0.270 
• R-Value Work: 0.253 

Literature

Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.

Bohl, C.E., Wu, Z., Miller, D.D., Bell, C.E., Dalton, J.T.

(2007) J.Biol.Chem. 282: 13648-13655

• PubMed: 17311914 
• DOI: 10.1074/jbc.M611711200


• PubMed Abstract: 
  

Cyproterone acetate (CPA) is a steroidal antiandrogen used clinically in the treatment of prostate cancer. Compared with steroidal agonists for the androgen receptor (AR) (e.g. dihydrotestosterone, R1881), CPA is bulkier in structure and therefore seemingly incompatible with the binding pockets observed in currently available x-ray crystal structures of the AR ligand-binding domain (LBD). We solved the x-ray crystal structure of the human AR LBD bound to CPA at 1.8A in the T877A variant, a mutation known to increase the agonist activity of CPA and therefore facilitate purification and crystal formation of the receptor.drug complex. The structure demonstrates that bulk from the 17alpha-acetate group of CPA induces movement of the Leu-701 side chain, which results in partial unfolding of the C-terminal end of helix 11 and displacement of the loop between helices 11 and 12 in comparison to all other AR LBD crystal structures published to date. This structural alteration leads to an expansion of the AR binding cavity to include an additional pocket bordered by Leu-701, Leu-704, Ser-778, Met-780, Phe-876, and Leu-880. Further, we found that CPA invokes transcriptional activation in the L701A AR at low nanomolar concentrations similar to the T877A mutant. Analogous mutations in the glucocorticoid receptor (GR) and progesterone receptor were constructed, and we found that CPA was also converted into a potent agonist in the M560A GR. Altogether, these data offer information for structure-based drug design, elucidate flexible regions of the AR LBD, and provide insight as to how CPA antagonizes the AR and GR.

---

Organizational Affiliation: 

Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, Ohio 43210, USA.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Androgen receptor	A	249	Homo sapiens	Mutation(s): 1  Gene Names: AR (DHTR, NR3C4)
Find proteins for P10275 (Homo sapiens) Go to Gene View: AR Go to UniProtKB:  P10275

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
CA4	A	CYPROTERONE ACETATE C24 H29 Cl O4 UWFYSQMTEOIJJG-FDTZYFLXSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
CA4	IC50: 23 - 18000 nM (99) BINDINGDB
CA4	Ki: 14 nM (99) BINDINGDB
CA4	Ki: 14 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.8 Å
• R-Value Free: 0.270 
• R-Value Work: 0.253 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 56.504	α = 90.00
b = 65.820	β = 90.00
c = 71.506	γ = 90.00

Software Package:

Software Name	Purpose
CrystalClear	data collection
SCALEPACK	data scaling
CNS	refinement
CrystalClear	data reduction
CNS	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2007-02-25 
• Released Date: 2007-03-27 
• Deposition Author(s): Bohl, C.E., Wu, Z., Miller, D.D., Bell, C.E., Dalton, J.T.

Revision History 

• Version 1.0: 2007-03-27
  Type: Initial release
• Version 1.1: 2008-05-01
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance